Polynucleotides are DNA-fragment molecules that signal dermal regeneration through specific receptor pathways. The injectable form (Plinest, Mastelli, others) has strong clinical evidence for skin quality improvement. The topical “polynucleotide cream” category claims similar mechanisms but contains different molecules at lower concentrations with much weaker evidence. Here’s what each actually does and where the marketing has gone too far.
Polynucleotides are linear chains of nucleotides (the molecular building blocks of DNA and RNA) at specific molecular weights designed to signal dermal regeneration. The injectable products — Plinest, Mastelli PN, Rejuran in the Korean market — have accumulated substantial clinical evidence over the past decade for skin quality improvement, dermal density, and reduction in fine lines and chronic inflammation.
The topical polynucleotide cream category emerged around 2020 as injectable popularity spread. Most topical formulations claim similar mechanisms to the injectables. The marketing implies that applying polynucleotides topically produces effects comparable to injection. The clinical reality is meaningfully different: the topical category contains different molecules at lower concentrations with much weaker evidence than the injectable category.
This distinction matters because the price point of topical polynucleotide products is often premium ($80-200+) based on the implied comparison with injectable treatments. The actual delivered effect is much smaller.
What injectable polynucleotides actually do
Injectable polynucleotides (typically polydeoxyribonucleotides or PDRN) deliver short DNA fragments directly into the dermal layer. The fragments bind to A2A adenosine receptors on fibroblasts and trigger downstream signaling that produces three documented effects.
First: collagen synthesis upregulation. The signaling stimulates fibroblast collagen production at rates exceeding baseline. The effect is measurable through ultrasound imaging of dermal density at 8-12 weeks post-treatment.
Second: chronic inflammation reduction. The A2A receptor signaling has direct anti-inflammatory effects that improve presentations like rosacea and persistent post-inflammatory states. The effect persists for months after treatment.
Third: microvascular improvement. The signaling supports capillary network maintenance in the dermal layer. Improved microcirculation contributes to overall skin quality and resilience.
The clinical evidence for injectable polynucleotides is solid. Multiple studies in the Italian dermatology literature (where Plinest was developed) and the broader European and Asian literature document the effects at the recommended injection protocols.
What topical polynucleotides claim
Topical polynucleotide products claim similar mechanisms to the injectables. The marketing positions these as “topical Rejuran” or “non-invasive polynucleotide therapy” or similar comparisons to injectable treatments.
The chemistry is meaningfully different. Most topical products contain shorter polynucleotide fragments or polynucleotide-related compounds (often derived from salmon DNA or other marine sources) at concentrations far below what the injectables deliver. The penetration through intact skin is limited — most topical polynucleotides remain on the surface or penetrate only into the stratum corneum.
The clinical evidence for topical polynucleotides is much weaker than for injectables. Some industry-sponsored studies show modest improvements in skin parameters; independent clinical evidence is sparse. The effect size, when measurable, is comparable to general humectants rather than to the dermal-density changes injectables produce.
The price-mechanism mismatch
Topical polynucleotide products are typically priced at premium tiers ($80-200+) based on the implied comparison with injectable treatments. The pricing doesn’t reflect the actual delivered mechanism.
For comparison: a course of injectable polynucleotides (typically 3-4 sessions over 2-4 months) costs $1,200-2,400 in most US markets. The injection delivers PDRN at concentrations and locations that produce the documented dermal effects.
A topical “polynucleotide cream” at $150 delivers polynucleotide-related compounds at minimal concentrations to the skin surface. The effect is dramatically smaller — at best comparable to a peptide-rich moisturizer at the same price.
The marketing comparison (“topical alternative to Plinest”) oversells what the topical category can deliver. The honest reading: topical polynucleotides may add modest barrier and hydration support; they don’t produce the dermal effects that injectables produce.
When topical polynucleotides might be worth using
Specific contexts where topical polynucleotide products may produce benefit:
Post-procedure adjunct use. After microneedling, radiofrequency, or laser procedures, the channels and increased permeability may allow topical polynucleotide penetration that wouldn’t occur on intact skin. Some clinical evidence supports adjunct use in this specific context.
As part of multi-active formulations where polynucleotides supplement rather than substitute for stronger actives. Combination products with peptides, growth factors, and polynucleotides may produce effects driven primarily by the other actives.
For users specifically seeking the lowest-active-load anti-aging routine. Polynucleotide-rich products produce minimal irritation. As a gentle addition to a routine that already includes retinoids and stronger actives, they may add incremental benefit.
What to skip in the topical category
Products positioned as “topical alternatives to injection.” The mechanism doesn’t translate; the marketing is misleading.
Products priced above $100 for polynucleotide alone. The active concentration doesn’t justify premium pricing.
Products claiming dramatic anti-aging results from polynucleotides alone. The evidence doesn’t support these claims for topical use.
Products without disclosed polynucleotide concentrations. The category has minimal regulatory oversight and unverified claims are common.
The injectable conversation
For users seriously considering polynucleotide treatment, the injectable conversation is the relevant one. The treatments are administered by dermatologists or trained aesthetic medicine practitioners. Costs vary by market ($300-600 per session in most US markets, lower in Korea and other Asian markets where the treatments are more widely available).
Typical protocol: 3-4 sessions at 4-week intervals, with results visible at 8-12 weeks post-completion. The effects persist for 6-12 months; maintenance sessions every 6-12 months sustain results.
Safety profile: well-tolerated with minimal side effects. The treatment is considered low-risk relative to other injectables (fillers, neuromodulators).
Best candidates: users with established skincare routine seeking incremental improvement in skin quality, dermal density, or chronic inflammation. Not a first-line treatment for severe photoaging or active medical conditions.
The honest framing
Injectable polynucleotides: evidence-based treatment with documented effects on dermal quality. Worth investigating for users in the appropriate context.
Topical polynucleotides: largely marketing-driven category with effects comparable to peptide-rich moisturizers at similar price points. The injectable comparison is misleading.
For users wanting topical anti-aging at reasonable price: retinaldehyde 0.05% + niacinamide + ceramide moisturizer + daily SPF produces measurable results without the polynucleotide premium pricing.
For users wanting the polynucleotide-specific effect: the injectable conversation with a dermatologist is the appropriate path.
FAQ
Do topical polynucleotides work? Modest effects on barrier and hydration. The dramatic claims comparing topical products to injectable treatments are misleading. The injectable form has strong clinical evidence; the topical form has much weaker evidence.
What’s the difference between Plinest and topical polynucleotide creams? Plinest delivers polydeoxyribonucleotide (PDRN) at therapeutic concentrations directly into the dermal layer via injection. Topical creams contain polynucleotide-related compounds at lower concentrations that remain mostly on the skin surface. The mechanisms are fundamentally different in delivery.
Is Rejuran the same as polynucleotide injection? Rejuran is a brand of polynucleotide injection developed in Korea. The mechanism is similar to Plinest and other PDRN injectables. The Korean market familiarity with Rejuran makes it widely available at competitive prices in Asian markets.
How much does polynucleotide injection cost? $300-600 per session in most US markets. Typical protocol of 3-4 sessions costs $1,200-2,400. Lower in Korean and some other Asian markets where treatments are more widely available.
Should I try topical polynucleotides before considering injection? The topical and injectable produce different effects with different evidence bases. Topical use as adjunct to a routine is reasonable; expecting topical to replicate injectable results is unrealistic.
References
- Squadrito F, Bitto A, Irrera N, et al.. Pharmacological activity and clinical use of PDRN. Front Pharmacol. 2017. PubMed.
- Veronesi F, Della Bella E, Cepollaro S, et al.. Novel therapeutic targets in osteoarthritis: narrative review on the role of PDRN. Drug Discov Today. 2017. PubMed.
Have a question about “Polynucleotides: topical creams versus injectable Plinest, honestly compared”?
Ask our editorial desk. Best questions become full follow-up articles, reviewed by our medical reviewer. No medical advice given in private — answers run as articles or not at all.